Splash Beverage finalizes joint venture with cannabinoid pharma group for CannEpil veterinary program

• Splash Beverage Group is finalizing a joint venture with an established cannabinoid pharmaceutical company to lead CannEpil’s veterinary drug development program.
• The move follows an expansion of Splash’s exclusive global CannEpil license into veterinary therapeutics, adding a second FDA-regulated development platform.
• Initial veterinary focus targets companion-animal oncology, chronic pain management, with canine indications first.
• Splash expects the partner to bring executives with experience advancing cannabinoid medicines through regulatory approval, with more details to be announced soon.
• Splash will pay Argent BioPharma a 10% royalty on net revenues from veterinary CannEpil applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Splash Beverage Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607290830PRIMZONEFULLFEED9800159) on July 29, 2026, and is solely responsible for the information contained therein.